Trial Profile
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- Acronyms TIM
- 05 Sep 2019 Status changed from recruiting to completed.
- 15 Aug 2018 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.
- 15 Aug 2018 Planned primary completion date changed from 30 Jul 2018 to 30 Jul 2019.